Stock Track | Adaptive Biotechnologies Soars 5.30% in Night Session on Strong Q1 Earnings Beat

Stock Track05-06 12:35

Adaptive Biotechnologies Corp's stock soared 5.30% during night session trading on Wednesday, following the release of its first-quarter 2026 financial results.

The significant price increase was driven by the company reporting better-than-expected quarterly performance. Adaptive Biotechnologies posted Q1 revenue of $70.874 million, which exceeded analyst estimates of $60.9 million by approximately 16.5% and represented a 35% increase year-over-year. The company also reported a quarterly loss per share of $0.13, beating the consensus estimate of a $0.17 loss by 23.5%.

Further bolstering investor sentiment, the company's net loss narrowed to $20 million compared to the same period last year, while adjusted EBITDA of -$2.5 million also came in significantly better than the -$6.55 million estimate. The company raised its full-year MRD revenue guidance to $260-$270 million, reflecting accelerating adoption of its clonoSEQ test, which saw volume increase 41% year-over-year to 32,595 tests delivered.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185383366?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 12:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185383366","market":"hk","top_or_hot":-1,"title":"Stock Track | Adaptive Biotechnologies Soars 5.30% in Night Session on Strong Q1 Earnings Beat","media":"Stock Track","content":"<p>Adaptive Biotechnologies Corp's stock soared 5.30% during night session trading on Wednesday, following the release of its first-quarter 2026 financial results.</p><p>The significant price increase was driven by the company reporting better-than-expected quarterly performance. Adaptive Biotechnologies posted Q1 revenue of $70.874 million, which exceeded analyst estimates of $60.9 million by approximately 16.5% and represented a 35% increase year-over-year. The company also reported a quarterly loss per share of $0.13, beating the consensus estimate of a $0.17 loss by 23.5%.</p><p>Further bolstering investor sentiment, the company's net loss narrowed to $20 million compared to the same period last year, while adjusted EBITDA of -$2.5 million also came in significantly better than the -$6.55 million estimate. The company raised its full-year MRD revenue guidance to $260-$270 million, reflecting accelerating adoption of its clonoSEQ test, which saw volume increase 41% year-over-year to 32,595 tests delivered.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Adaptive Biotechnologies Soars 5.30% in Night Session on Strong Q1 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Adaptive Biotechnologies Soars 5.30% in Night Session on Strong Q1 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 12:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Adaptive Biotechnologies Corp's stock soared 5.30% during night session trading on Wednesday, following the release of its first-quarter 2026 financial results.</p><p>The significant price increase was driven by the company reporting better-than-expected quarterly performance. Adaptive Biotechnologies posted Q1 revenue of $70.874 million, which exceeded analyst estimates of $60.9 million by approximately 16.5% and represented a 35% increase year-over-year. The company also reported a quarterly loss per share of $0.13, beating the consensus estimate of a $0.17 loss by 23.5%.</p><p>Further bolstering investor sentiment, the company's net loss narrowed to $20 million compared to the same period last year, while adjusted EBITDA of -$2.5 million also came in significantly better than the -$6.55 million estimate. The company raised its full-year MRD revenue guidance to $260-$270 million, reflecting accelerating adoption of its clonoSEQ test, which saw volume increase 41% year-over-year to 32,595 tests delivered.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADPT","symbol_name":"Adaptive Biotechnologies Corp","start_time":0,"source_url":"","article_id":"1185383366","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185383366","pubTimestamp":1778042116,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Adaptive Biotechnologies Corp's stock soared 5.30% during night session trading on Wednesday, following the release of its first-quarter 2026 financial results.The significant price increase was...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADPT":"Adaptive Biotechnologies Corp"},"translate_title":"股票追踪|Adaptive Biotechnologies夜盘飙升5.30%，第一季度盈利强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":1},"content_text":"Adaptive Biotechnologies Corp's stock soared 5.30% during night session trading on Wednesday, following the release of its first-quarter 2026 financial results.The significant price increase was driven by the company reporting better-than-expected quarterly performance. Adaptive Biotechnologies posted Q1 revenue of $70.874 million, which exceeded analyst estimates of $60.9 million by approximately 16.5% and represented a 35% increase year-over-year. The company also reported a quarterly loss per share of $0.13, beating the consensus estimate of a $0.17 loss by 23.5%.Further bolstering investor sentiment, the company's net loss narrowed to $20 million compared to the same period last year, while adjusted EBITDA of -$2.5 million also came in significantly better than the -$6.55 million estimate. The company raised its full-year MRD revenue guidance to $260-$270 million, reflecting accelerating adoption of its clonoSEQ test, which saw volume increase 41% year-over-year to 32,595 tests delivered.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185383366","isCrawlerRequest":true}